1. Volume 9, Issue 12, Pages 1181-1190 (December 2017)
Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the Treatment of Hemiparesis in Adults With Upper Limb Spasticity Previously Treated With Botulinum Toxin: Subanalysis From a Phase 3 Randomized Controlled Trial 
Christina Marciniak, MD, Peter McAllister, MD, Heather Walker, MD, Allison Brashear, MD, Steven Edgley, MD, Thierry Deltombe, MD, Svetlana Khatkova, MD, Marta Banach, MD, Fatma Gul, MD, MMM, Claire Vilain, MD, Philippe Picaut, MD, Anne-Sophie Grandoulier, MSc, Jean-Michel Gracies, MD, PhD Z. Ayyoub, M. Banach, D. Bensmail, A.R. Bentivoglio, F.C. Boyer, A. Brashear, A. Csanyi, T. Deltombe, Z. Denes, S. Edgley, F. Gul, J.-M. Gracies, P. Hedera, S. Isaacson, M.-E. Isner-Horobeti, R. Jech, A. Kaminska, S. Khatkova, S. Kocer, T. Lejeune, P. McAllister, C. Marciniak, P. Marque, M. O’Dell, O. Remy-Neris, B. Rubin, M. Rudzinska-Bar, D. Simpson, A. Skoromets, S.L. Timerbaeva, P. Valkovic, M. Vecchio, H. Walker, M. Wimmer Christina Marciniak, MD, Peter McAllister, MD, Heather Walker, MD, Allison Brashear, MD, Steven Edgley, MD, Thierry Deltombe, MD, Svetlana Khatkova, MD, Marta Banach, MD, Fatma Gul, MD, MMM, Claire Vilain, MD, Philippe Picaut, MD, Anne-Sophie Grandoulier, MSc, Jean-Michel Gracies, MD, PhD Z. Ayyoub, M. Banach, D. Bensmail, A.R. Bentivoglio, F.C. Boyer, A. Brashear, A. Csanyi, T. Deltombe, Z. Denes, S. Edgley, F. Gul, J.-M. Gracies, P. Hedera, S. Isaacson, M.-E. Isner-Horobeti, R. Jech, A. Kaminska, S. Khatkova, S. Kocer, T. Lejeune, P. McAllister, C. Marciniak, P. Marque, M. O’Dell, O. Remy-Neris, B. Rubin, M. Rudzinska-Bar, D. Simpson, A. Skoromets, S.L. Timerbaeva, P. Valkovic, M. Vecchio, H. Walker, M. Wimmer 
PM&R 
Volume 9, Issue 12, Pages (December 2017)
DOI: /j.pmrj
Copyright © 2017 American Academy of Physical Medicine and Rehabilitation Terms and Conditions

2. Figure 1
Patient population. AboBoNT-A = abobotulinumtoxinA; BoNT-A = botulinum toxin A.
PM&R 2017 9, DOI: ( /j.pmrj )
Copyright © 2017 American Academy of Physical Medicine and Rehabilitation Terms and Conditions

3. Figure 2
Responders to abobotulinumtoxinA according to MAS score improvement for the PTMG. Responders were defined as those subjects with a ≥1 grade improvement on the MAS for the PTMG. AboBoNT-A = abobotulinumtoxinA; MAS = Modified Ashworth Scale; PTMG = primary target muscle group.
PM&R 2017 9, DOI: ( /j.pmrj )
Copyright © 2017 American Academy of Physical Medicine and Rehabilitation Terms and Conditions

4. Figure 3
Clinical improvement with abobotulinumtoxinA according to PGA score ≥1. AboBoNT-A = abobotulinumtoxinA; PGA = Physician Global Assessment.
PM&R 2017 9, DOI: ( /j.pmrj )
Copyright © 2017 American Academy of Physical Medicine and Rehabilitation Terms and Conditions

5. Figure 4
Subjects with ≥1 grade decrease in DAS score for the principal target of treatment. AboBoNT-A = abobotulinumtoxinA; DAS = Disability Assessment Scale.
PM&R 2017 9, DOI: ( /j.pmrj )
Copyright © 2017 American Academy of Physical Medicine and Rehabilitation Terms and Conditions